Many molecular lesions related to MDS and AML development including mutations in FLT3, NRAS/KRAS and IDH1/2 affect intracellular ROS production, thus potentially promoting ROS-mediated oncogenic signaling (94). The gene discussed is NRAS; the disease is acute myeloid leukemia.